Abstract
New concept of evaluating the effect of natalizumab on the activity of remitting multiple sclerosis judged by number of relapses, progression of disability and MRI activity (both gadolinium-enhancing and new T2 lesions). It is combined score which has not been possible to apply yet as none up to now used therapy has been effective enough